Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. YCBD
YCBD logo

YCBD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy cbdMD Inc (YCBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.720
1 Day change
4.80%
52 Week Range
2.560
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, cbdMD Inc (YCBD) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators are neutral to bearish, there are no significant trading trends, and no proprietary trading signals suggest immediate action. While the company has shown revenue growth and is undergoing strategic changes, the lack of valuation data, weak technicals, and absence of strong catalysts make it prudent to hold off on investing at this time.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 57.411, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.716, with resistance at 0.766 and support at 0.666. Overall, the technical outlook is neutral to bearish.

Positive Catalysts

  • The company reported 19% year-over-year and 12% sequential revenue growth, driven by strong performance in core brands and integration of Bluebird Botanicals. Appointment of Wade Brown as Chief Marketing Officer to drive brand expansion and evolve the company into a multi-brand wellness platform.

Neutral/Negative Catalysts

  • Technical indicators do not suggest a strong upward trend. No significant trading trends from hedge funds or insiders. Lack of valuation data and no recent activity from influential figures or Congress trading.

Financial Performance

The company reported strong revenue growth in the latest quarter (19% YoY and 12% sequential). However, no detailed financial data or valuation metrics were provided to assess profitability or other key metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes were provided in the data.

Wall Street analysts forecast YCBD stock price to rise
1 Analyst Rating
Wall Street analysts forecast YCBD stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.687
sliders
Low
2
Averages
2
High
2
Current: 0.687
sliders
Low
2
Averages
2
High
2
Maxim
Buy
downgrade
$3 -> $2
AI Analysis
2025-08-20
Reason
Maxim
Price Target
$3 -> $2
AI Analysis
2025-08-20
downgrade
Buy
Reason
Maxim lowered the firm's price target on cbdMD to $2 from $3 and keeps a Buy rating on the shares. The firm cites the company's Q3 loss coming in wider than expected amid softness in demand and regulatory uncertainties, the analyst tells investors in a research note. Maxim adds that while the company has partnered with industry advocacy groups to engage legislators and prioritize compliance with product quality and labeling requirements, it expects regulatory headwinds to persist, limiting growth through 2026.

People Also Watch